Abstract
To retrospectively analyze the risk factors and the prognosis according to the number of lymph node metastases (LNMs) in different neck compartments in papillary thyroid carcinoma (PTC) patients. In total, 962 patients with PTC were enrolled in this study. According to the methods of the 2015 American Thyroid Association, the treatment response of the patients was divided into a good prognosis and a poor prognosis. First, their clinical characteristics were summarized. Then, according to whether they had LNMs and the number of LNMs in different neck compartments, their risk factors and their prognosis were analyzed. Male sex, younger (< 45 years), extrathyroid extension (ETE), T1 staging and higher stimulated thyroglobulin (sTg) levels were the risk factors for LNM. The cutoff for a poor prognosis of the number of LNMs was > 4. Male sex, younger age, higher sTg levels and ETE were correlated with LNM > 4. Furthermore, the cutoffs for a poor prognosis of central lymph node metastasis (CLNM), lateral lymph node metastasis (LLNM) and CLNM + LLNM were > 6, > 1 and > 5, respectively. Younger age and ETE were strongly correlated with CLNM > 6. Male sex, younger age, higher sTg levels and ETE were correlated with LLNM > 1. Younger age, ETE and higher sTg levels were correlated with CLNM + LLNM > 5. Further analysis revealed a positive correlation between CLNM and LLNM. We should pay more attention to LNMs in PTC patients who are male, are of a younger age, have ETE, T1 staging and have higher sTg levels. The neck regional LNMs should be correctly evaluated to guide the surgical options for the neck LNMs in PTC. When the number of LNMs in different neck compartments has exceeded the cutoff value, they can be considered as predictors of the outcome of 131I treatment.
Similar content being viewed by others
Data availability
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
References
Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133. https://doi.org/10.1089/thy.2015.0020.
Vayisoglu Y, Ozcan C. Involvement of level IIb lymph node metastasis and dissection in thyroid cancer. Gland Surg. 2013;2:180–5. https://doi.org/10.3978/j.issn.2227-684X.2013.10.04.
Kim YS, Park WC. Clinical predictors of right upper paraesophageal lymph node metastasis from papillary thyroid carcinoma. World J Surg Oncol. 2012;10:164. https://doi.org/10.1186/1477-7819-10-164.
Machens A, Holzhausen HJ, Dralle H. Skip metastases in thyroid cancer leaping the central lymph node compartment. Arch Surg. 2004;139:43–5. https://doi.org/10.1001/archsurg.139.1.43.
Gimm O, Rath FW, Dralle H. Pattern of lymph node metastases in papillary thyroid carcinoma. Br J Surg. 1998;85:252–4. https://doi.org/10.1046/j.1365-2168.1998.00510.x.
Podnos YD, Smith D, Lawrence DW, Ellenhorn JDI. The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. Am Surg. 2005;71:731–4. https://doi.org/10.3171/2014.7.PEDS13318.
Keum HS, Ji YB, Kim JM, et al. Optimal surgical extent of lateral and central neck dissection for papillary thyroid carcinoma located in one lobe with clinical lateral lymph node metastasis. Word J Surg Oncol. 2012. https://doi.org/10.1186/1477-7819-10-221.
Song J, Yan T, Qiu W, Fan Y, Yang Z. Clinical analysis of risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma: a retrospective study of 3686 patients. Cancer Manag Res. 2020;12:2523–30. https://doi.org/10.2147/CMAR.S250163.
Scheumann GF, Gimm O, Wegener G, Hundeshagen H, Dralle H. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg. 1994;18(4):559–68. https://doi.org/10.1007/BF00353765.
Wang TS, Dubner S, Sznyter LA, Heller KS. Incidence of metastatic well-differentiated thyroid cancer in cervical lymph nodes. Arch Otolaryngol Head Neck Surg. 2004;130:110–3. https://doi.org/10.1001/archotol.130.1.110.
Wada N, Duh QY, Sugino K, et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg. 2003;237:399–407. https://doi.org/10.1097/01.SLA.0000055273.58908.19.
Chow SM, Law SC, Chan JK, Au SK, Yau S, Lau WH. Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality. Cancer. 2003;98:31–40. https://doi.org/10.1002/cncr.11442.
Mercante G, Frasoldati A, Pedroni C, et al. Prognostic factors affecting neck lymph node recurrence and distant metastasis in papillary microcarcinoma of the thyroid: results of a study in 445 patients. Thyroid. 2009;19:707–16. https://doi.org/10.1089/thy.2008.0270.
Hasney CP, Amedee RG. What is the appropriate extent of lateral neck dissection in the treatment of metastatic well-differentiated thyroid carcinoma? Laryngoscope. 2010;120:1716–7. https://doi.org/10.1002/lary.20994.
Beasley NJ, Lee J, Eski S, Walfish P, Witterick I, Freeman JL. Impact of nodal metastases on prognosis in patients with well-differentiated thyroid cancer. Arch Otolaryngol-Head Neck Surg. 2002;128:825–8. https://doi.org/10.1001/archotol.128.7.825.
Liu F, Kuo S, Hsueh C, Chao T, Lin J. Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis. J Surg Oncol. 2015;112:149–54. https://doi.org/10.1002/jso.23967.
Sivanandan R, Soo KC. Pattern of cervical lymph node metastases from papillary carcinoma of the thyroid. Br J Surg. 2001. https://doi.org/10.1046/j.0007-1323.2001.01843.x.
Roh JL, Kim JM, Park CI. Lateral cervical lymph node metastases from papillary thyroid carcinoma: pattern of nodal metastases and optimal strategy for neck dissection. Ann Surg Oncol. 2008;15:1177–82. https://doi.org/10.1245/s10434-008-9813-5.
Attard A, Paladino NC, Lo Monte AI, et al. Skip metastases to lateral cervical lymph nodes in differentiated thyroid cancer: a systematic review. BMC Surg. 2019;18:112. https://doi.org/10.1186/s12893-018-0435-y.
Rajeev P, Ahmed S, Ezzat TM, Sadler GP, Mihai R. The number of positive lymph nodes in the central compartment has prognostic impact in papillary thyroid cancer. Langenbecks Arch Surg. 2013;398:377–82. https://doi.org/10.1007/s00423-012-1041-6.
Gong Y, Yang J, Yan S, et al. Pattern of and clinicopathologic risk factors for lateral lymph node metastases in papillary thyroid carcinoma patients with lateral cervical lymphadenopathy. Medicine (Baltimore). 2018;97:e12263. https://doi.org/10.1097/MD.0000000000012263.
Stulak JM, Grant CS, Farley DR, et al. Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg. 2006. https://doi.org/10.1001/archsurg.141.5.489.
Di Meo G, Sgaramella LI, Ferraro V, Prete FP, Gurrado A, Testini M. Parathyroid carcinoma in multiple endocrine neoplasm type 1 syndrome: case report and systematic literature review. Clin Exp Med. 2018;18:585–93.
Leboulleux S, Rubino C, Baudin E, et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab. 2005;90:5723–9. https://doi.org/10.1210/jc.2005-0285.
Zhan S, Luo D, Ge W, Zhang B, Wang T. Clinicopathological predictors of occult lateral neck lymph node metastasis in papillary thyroid cancer: a meta-analysis. Head Neck. 2019;41:2441–9. https://doi.org/10.1002/hed.25762.
Xue S, Wang P, Liu J, Chen G. Radioactive iodine ablation decrease recurrences in papillary thyroid microcarcinoma with lateral lymph node metastasis in Chinese patients. World J Surg. 2017;41:3139–46. https://doi.org/10.1007/s00268-017-4134-0.
Creach KM, Siegel BA, Nussenbaum B, Grigsby PW. Radioactive iodine therapy decreases recurrence in thyroid papillary microcarcinoma. ISRN Endocrinol. 2012;2012:816386. https://doi.org/10.5402/2012/816386.
Jeon MJ, Kim WG, Choi YM, et al. Features predictive of distant metastasis in papillary thyroid microcarcinomas. Thyroid. 2016;26:161–8. https://doi.org/10.1089/thy.2015.0375.
Adam MA, Pura J, Goffredo P, et al. Presence and number of lymph node metastases are associated with compromised survival for patients younger than age 45 years with papillary thyroid cancer. J Clin Oncol. 2015;33:2370–5. https://doi.org/10.1200/JCO.2014.59.8391.
Zaydfudim V, Feurer ID, Griffin MR, Phay JE. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery. 2008;144:1070–7. https://doi.org/10.1016/j.surg.2008.08.034.
Nixon IJ, Kuk D, Wreesmann V, et al. Defining a valid age cutoff in staging of well-differentiated thyroid cancer. Ann Surg Oncol. 2016;23:410–5. https://doi.org/10.1245/s10434-015-4762-2.
Wang X, Tan J, Zheng W, Li N. A retrospective study of the clinical features in papillary thyroid microcarcinoma depending on age. Nucl Med Commun. 2018;39:713–9. https://doi.org/10.1097/MNM.0000000000000859.
Tao Y, Wang C, Li L, et al. Clinicopathological features for predicting central and lateral lymph node metastasis in papillary thyroid microcarcinoma: analysis of 66 cases that underwent central and lateral lymph node dissection. Mol Clin Oncol. 2017;6:49–55. https://doi.org/10.3892/mco.2016.1085.
Zhao C, Jiang W, Gao Y, Niu W, Zhang X, Xin L. Risk factors for lymph node metastasis (LNM) in patients with papillary thyroid microcarcinoma (PTMC): role of preoperative ultrasound. J Int Med Res. 2017;45:1221–30. https://doi.org/10.1177/0300060517708943.
Oh HS, Park S, Kim M, et al. Young age and male sex are predictors of large-volume central neck lymph node metastasis in clinical n0 papillary thyroid microcarcinomas. Thyroid. 2017;27:1285–90. https://doi.org/10.1089/thy.2017.0250.
Siddiqui S, White MG, Antic T, et al. Clinical and pathologic predictors of lymph node metastasis and recurrence in papillary thyroid microcarcinoma. Thyroid. 2016;26:807–15. https://doi.org/10.1089/thy.2015.0429.
Roh JL, Kim JM, Park CI. Central lymph node metastasis of unilateral papillary thyroid carcinoma: patterns and factors predictive of nodal metastasis, morbidity, and recurrence. Ann Surg Oncol. 2011;18:2245–50. https://doi.org/10.1245/s10434-011-1600-z.
Koo BS, Choi EC, Yoon YH, Kim DH, Kim EH, Lim YC. Predictive factors for ipsilateral or contralateral central lymph node metastasis in unilateral papillary thyroid carcinoma. Ann Surg. 2009;249:840–4. https://doi.org/10.1097/SLA.0b013e3181a40919.
Machens A, Holzhausen HJ, Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer. 2005;103:2269–73. https://doi.org/10.1002/cncr.21055.
Luo Y, Zhao Y, Chen K, et al. Clinical analysis of cervical lymph node metastasis risk factors in patients with papillary thyroid microcarcinoma. J Endocrinol Invest. 2019;42:227–36. https://doi.org/10.1007/s40618-018-0908-y.
Zubair Hussain S, Zaman MU, Malik S, et al. Preablation stimulated thyroglobulin/TSH ratio as a predictor of successful I(131)remnant ablation in patients with differentiated thyroid cancer following total thyroidectomy. J Thyroid Res. 2014;2014:610273. https://doi.org/10.1155/2014/610273.
Trevizam PG, Tagliarini JV, Castilho EC, de Alencar MM, Kiy Y, Mazeto GMFS. Thyroglobulin levels and thyroglobulin/thyrotropin ratio could predict the success of the ablative/therapeutic 131I in the differentiated thyroid cancers. Endocr Res. 2017;42(1):42–8. https://doi.org/10.3109/07435800.2016.1173056.
González C, Aulinas A, Colom C, et al. Thyroglobulin as early prognostic marker to predict remission at 18–24 months in differentiated thyroid carcinoma. Clin Endocrinol. 2014;80:301–6. https://doi.org/10.1111/cen.12282.
Ito Y, Higashiyama T, Takamura Y, Kobayashi K, Miya A, Miyauchi A. Prognosis of patients with papillary thyroid carcinoma located in one lobe showing lateral node metastasis in the contralateral but not ipsilateral compartment. J Thyroid Res. 2012;2012:953603. https://doi.org/10.1155/2012/953603.
Zhao S, Jia X, Fan X, et al. Association of obesity with the clinicopathological features of thyroid cancer in a large, operative population: a retrospective case-control study. Medicine (Baltimore). 2019;98(50):e18213. https://doi.org/10.1097/MD.0000000000018213.
Machens A, Holzhausen HJ, Lautenschläger C, Thanh PN, Dralle H. Enhancement of lymph node metastasis and distant metastasis of thyroid carcinoma. Cancer. 2003;98(4):712–9. https://doi.org/10.1002/cncr.11581.
Huang Y, Chang A, Zhou W, Zhao H, Zhuo X. IGFBP3 as an indicator of lymph node metastasis and unfavorable prognosis for papillary thyroid carcinoma. Clin Exp Med. 2020. https://doi.org/10.1007/s10238-020-00642-3.
Acknowledgements
Wei Zheng has a Nation Natural Science Foundation of China named ‘The optimal strategy for the establishment of Graves’ Disease mice model and targeted therapy research of ICAM-1 and TSHR’ (No. 81601523).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
The ethical, methodological and protocol aspects of this investigation were approved by the institutional review board and ethic committee of Tianjin Medical University General Hospital. We confirm that all methods in the current study were carried out in accordance with the relevant guidelines and regulations.
Informed consent
Written informed consents were provided by the participants to enter in this study, so every people participated in our study voluntarily and comprehended all aspects about the research.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Rui, Z.Y., Liu, Y., Zheng, W. et al. A retrospective study of the risk factors and the prognosis in patients with papillary thyroid carcinoma depending on the number of lymph node metastasis. Clin Exp Med 21, 277–286 (2021). https://doi.org/10.1007/s10238-020-00675-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10238-020-00675-8